Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Add To Watchlist

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc.

Business Wire February 23, 2015

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Business Wire February 23, 2015

Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference

Business Wire February 5, 2015

U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz(TM) (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults

Business Wire January 29, 2015

Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors

GlobeNewswire January 29, 2015

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results

Business Wire January 27, 2015

Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman

Business Wire January 20, 2015

Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors

Business Wire January 13, 2015

Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies

Business Wire January 12, 2015

CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early

Business Wire January 11, 2015

Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference

Business Wire January 6, 2015

Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic Diseases

Business Wire January 5, 2015

Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration

Business Wire December 22, 2014

Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)

Business Wire December 22, 2014

Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27

Business Wire December 17, 2014

Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

Business Wire December 10, 2014

Bristol-Myers Squibb Announces Dividend

Business Wire December 9, 2014

Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

Business Wire December 8, 2014

Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients with Hepatitis B and C in China and India

Business Wire December 3, 2014

Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Million in New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries

Business Wire December 1, 2014